{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:07:06Z","timestamp":1794712026332,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41591-026-04455-x","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T18:46:27Z","timestamp":1780253187000},"page":"2878-2887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["MAGE-A4\/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and\/or refractory solid tumors: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-4087","authenticated-orcid":false,"given":"Martin","family":"Wermke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ochsenreither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1276-7802","authenticated-orcid":false,"given":"Dirk","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-4048","authenticated-orcid":false,"given":"Heiko","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalen","family":"Bleckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8058-8884","authenticated-orcid":false,"given":"Farastuk","family":"Bozorgmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Groepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Haenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S.","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max-Felix","family":"H\u00e4ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-4584","authenticated-orcid":false,"given":"Daniel","family":"Heudobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-8174","authenticated-orcid":false,"given":"Norbert","family":"Hilf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-2140","authenticated-orcid":false,"given":"Meike","family":"Hutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mayer-Mokler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Missel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-3024","authenticated-orcid":false,"given":"Manuel","family":"Ruh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Veremchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1650-3466","authenticated-orcid":false,"given":"Moritz","family":"Kleemiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-6639","authenticated-orcid":false,"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-7137","authenticated-orcid":false,"given":"Simon","family":"Laban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Spoerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-8760","authenticated-orcid":false,"given":"Cedrik Michael","family":"Britten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-1920","authenticated-orcid":false,"given":"Carsten","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"4455_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974\u2013977 (2008).","journal-title":"Science"},{"key":"4455_CR2","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle, P. A. & Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941\u20134944 (2009).","journal-title":"Cancer Res."},{"key":"4455_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/314628a0","volume":"314","author":"UD Staerz","year":"1985","unstructured":"Staerz, U. D., Kanagawa, O. & Bevan, M. J. Hybrid antibodies can target sites for attack by T cells. Nature 314, 628\u2013631 (1985).","journal-title":"Nature"},{"key":"4455_CR4","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","volume":"133","author":"G Albayrak","year":"2025","unstructured":"Albayrak, G., Wan, P. K., Fisher, K. & Seymour, L. W. T cell engagers: expanding horizons in oncology and beyond. Br. J. Cancer 133, 1241\u20131249 (2025).","journal-title":"Br. J. Cancer"},{"key":"4455_CR5","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3390\/cells10092379","volume":"10","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. Evolution of CD8+ T cell receptor (TCR) engineered therapies for the treatment of cancer. Cells 10, 2397 (2021).","journal-title":"Cells"},{"key":"4455_CR6","doi-asserted-by":"publisher","first-page":"S681","DOI":"10.1016\/j.annonc.2024.08.1060","volume":"35","author":"M Wermke","year":"2024","unstructured":"Wermke, M. et al. 1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4\/8-directed half-life extended TCR bispecific, in phase I dose escalation. Ann. Oncol. 35, S681\u2013S682 (2024).","journal-title":"Ann. Oncol."},{"key":"4455_CR7","doi-asserted-by":"publisher","unstructured":"Bunk, S. et al. 1319 Next-generation TCR bispecifics (TCER\u00ae) targeting peptide-HLA antigens for the treatment of patients with solid tumors. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.1319 (2022).","DOI":"10.1136\/jitc-2022-SITC2022.1319"},{"key":"4455_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2009.05.010","volume":"68","author":"Y Shigematsu","year":"2010","unstructured":"Shigematsu, Y. et al. Clinical significance of cancer\/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer 68, 105\u2013110 (2010).","journal-title":"Lung Cancer"},{"key":"4455_CR9","first-page":"3513","volume":"8","author":"M Wang","year":"2015","unstructured":"Wang, M. et al. Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 8, 3513\u20133528 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"4455_CR10","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.3892\/or.2016.4600","volume":"35","author":"M Brisam","year":"2016","unstructured":"Brisam, M. et al. Expression of MAGE-A1-A12 subgroups in the invasive tumor front and tumor center in oral squamous cell carcinoma. Oncol. Rep. 35, 1979\u20131986 (2016).","journal-title":"Oncol. Rep."},{"key":"4455_CR11","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.0.CO;2-7","volume":"85","author":"K Tahara","year":"1999","unstructured":"Tahara, K. et al. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer 85, 1234\u20131240 (1999).","journal-title":"Cancer"},{"key":"4455_CR12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1158\/1078-0432.CCR-04-1365","volume":"11","author":"M Li","year":"2005","unstructured":"Li, M. et al. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin. Cancer Res. 11, 1809\u20131814 (2005).","journal-title":"Clin. Cancer Res."},{"key":"4455_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/sj.bjc.6601968","volume":"91","author":"E Bar-Haim","year":"2004","unstructured":"Bar-Haim, E. et al. MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. Br. J. Cancer 91, 398\u2013407 (2004).","journal-title":"Br. J. Cancer"},{"key":"4455_CR14","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1158\/0008-5472.CAN-05-3327","volume":"66","author":"T Peikert","year":"2006","unstructured":"Peikert, T., Specks, U., Farver, C., Erzurum, S. C. & Comhair, S. A. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res. 66, 4693\u20134700 (2006).","journal-title":"Cancer Res."},{"key":"4455_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00262-006-0228-5","volume":"56","author":"PM Alves","year":"2007","unstructured":"Alves, P. M. et al. Molecular and immunological evaluation of the expression of cancer\/testis gene products in human colorectal cancer. Cancer Immunol. Immunother. 56, 839\u2013847 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"4455_CR16","first-page":"713","volume":"53","author":"A Fujiwara-Kuroda","year":"2018","unstructured":"Fujiwara-Kuroda, A. et al. Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status. Int. J. Oncol. 53, 713\u2013724 (2018).","journal-title":"Int. J. Oncol."},{"key":"4455_CR17","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","volume":"12","author":"C Barrow","year":"2006","unstructured":"Barrow, C. et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12, 764\u2013771 (2006).","journal-title":"Clin. Cancer Res."},{"key":"4455_CR18","doi-asserted-by":"publisher","first-page":"e104099","DOI":"10.1371\/journal.pone.0104099","volume":"9","author":"S Daudi","year":"2014","unstructured":"Daudi, S. et al. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS ONE 9, e104099 (2014).","journal-title":"PLoS ONE"},{"key":"4455_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4161\/cbt.12.3.15949","volume":"12","author":"MM Forghanifard","year":"2011","unstructured":"Forghanifard, M. M. et al. Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy. Cancer Biol. Ther. 12, 191\u2013197 (2011).","journal-title":"Cancer Biol. Ther."},{"key":"4455_CR20","first-page":"3937","volume":"17","author":"T Kakimoto","year":"2019","unstructured":"Kakimoto, T. et al. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma. Oncol. Lett. 17, 3937\u20133943 (2019).","journal-title":"Oncol. Lett."},{"key":"4455_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark. Res. 8, 49 (2020).","journal-title":"Biomark. Res."},{"key":"4455_CR22","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1158\/2767-9764.CRC-23-0121","volume":"3","author":"A Newey","year":"2023","unstructured":"Newey, A. et al. Multifactorial remodeling of the cancer immunopeptidome by IFN\u03b3. Cancer Res. Commun. 3, 2345\u20132357 (2023).","journal-title":"Cancer Res. Commun."},{"key":"4455_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0198-8859(90)90113-4","volume":"29","author":"J Borst","year":"1990","unstructured":"Borst, J. et al. BMA031, a monoclonal antibody suited to identify the T-cell receptor \u03b1\u03b2\/CD3 complex on viable human T lymphocytes in normal and disease states. Hum. Immunol. 29, 175\u2013188 (1990).","journal-title":"Hum. Immunol."},{"key":"4455_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93842-0","volume":"11","author":"L Haber","year":"2021","unstructured":"Haber, L. et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci. Rep. 11, 14397 (2021).","journal-title":"Sci. Rep."},{"key":"4455_CR25","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","volume":"17","author":"D Mandikian","year":"2018","unstructured":"Mandikian, D. et al. Relative target affinities of T-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol. Cancer Ther. 17, 776\u2013785 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"4455_CR26","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.2967\/jnumed.120.241877","volume":"61","author":"FV Suurs","year":"2020","unstructured":"Suurs, F. V. et al. The biodistribution of a CD3 and EpCAM bispecific T-cell engager is driven by the CD3 arm. J. Nucl. Med. 61, 1594\u20131601 (2020).","journal-title":"J. Nucl. Med."},{"key":"4455_CR27","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1182\/blood-2022-165937","volume":"140","author":"S Bunk","year":"2022","unstructured":"Bunk, S. et al. IMA402, an off-the-shelf, next-generation TCR bispecific (TCER\u00ae) for efficiently targeting an HLA-presented peptide from the pan-cancer antigen PRAME. Blood 140, 9089\u20139090 (2022).","journal-title":"Blood"},{"key":"4455_CR28","doi-asserted-by":"publisher","first-page":"S888","DOI":"10.1016\/j.annonc.2022.07.879","volume":"33","author":"S Missel","year":"2022","unstructured":"Missel, S. et al. 753P Targeting solid tumors with IMA402, a next-generation bispecific T cell engaging receptor against PRAME. Ann, Oncol. 33, S888 (2022).","journal-title":"Ann, Oncol."},{"key":"4455_CR29","first-page":"18","volume":"4","author":"P Zajac","year":"2017","unstructured":"Zajac, P. et al. MAGE-A antigens and cancer immunotherapy. Front. Med. (Lausanne) 4, 18 (2017).","journal-title":"Front. Med. (Lausanne)"},{"key":"4455_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201700284","volume":"18","author":"J Fritsche","year":"2018","unstructured":"Fritsche, J. et al. Translating immunopeptidomics to immunotherapy-decision-making for patient and personalized target selection. Proteomics 18, e1700284 (2018).","journal-title":"Proteomics"},{"key":"4455_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2531223","volume":"17","author":"C Bergamaschi","year":"2025","unstructured":"Bergamaschi, C. et al. Innovative strategies for T cell engagers for cancer immunotherapy. MAbs 17, 2531223 (2025).","journal-title":"MAbs"},{"key":"4455_CR32","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4455_CR33","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn, M. J. et al. Tarlatamab for patients with previously treated small-cell lung cancer. N. Engl. J. Med. 389, 2063\u20132075 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4455_CR34","doi-asserted-by":"publisher","first-page":"e006747","DOI":"10.1136\/jitc-2023-006747","volume":"11","author":"O Hamid","year":"2023","unstructured":"Hamid, O. et al. Tebentafusp in combination with durvalumab and\/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. J. Immunother. Cancer 11, e006747 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"4455_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48479-8","volume":"15","author":"NH Segal","year":"2024","unstructured":"Segal, N. H. et al. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials. Nat. Commun. 15, 4091 (2024).","journal-title":"Nat. Commun."},{"key":"4455_CR36","doi-asserted-by":"publisher","first-page":"ltad013","DOI":"10.1093\/immadv\/ltad013","volume":"3","author":"WM Zhu","year":"2023","unstructured":"Zhu, W. M. & Middleton, M. R. Combination therapies for the optimisation of bispecific T-cell engagers in cancer treatment. Immunother. Adv. 3, ltad013 (2023).","journal-title":"Immunother. Adv."},{"key":"4455_CR37","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke, M. et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat. Med. 31, 2365\u20132374 (2025).","journal-title":"Nat. Med."},{"key":"4455_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Primers 6, 38 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"4455_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/cpt.393","volume":"100","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Mechanistic projection of first-in-human dose for bispecific immunomodulatory P-cadherin LP-DART: an integrated PK\/PD modeling approach. Clin. Pharmacol. Ther. 100, 232\u2013241 (2016).","journal-title":"Clin. Pharmacol. Ther."},{"key":"4455_CR40","doi-asserted-by":"publisher","first-page":"e000213","DOI":"10.1136\/jitc-2019-000213","volume":"8","author":"TH Schaller","year":"2020","unstructured":"Schaller, T. H. et al. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. J. Immunother. Cancer 8, e000213 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"4455_CR41","doi-asserted-by":"publisher","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","volume":"15","author":"K Ball","year":"2023","unstructured":"Ball, K., Dovedi, S. J., Vajjah, P. & Phipps, A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs 15, 2181016 (2023).","journal-title":"MAbs"},{"key":"4455_CR42","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares, L. et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J. Clin. Oncol. 41, 2893\u20132903 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4455_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo6135","volume":"14","author":"GB Kim","year":"2022","unstructured":"Kim, G. B. et al. Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy. Sci. Transl. Med. 14, eabo6135 (2022).","journal-title":"Sci. Transl. Med."}],"updated-by":[{"DOI":"10.1038\/s41591-026-04519-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04455-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:01:48Z","timestamp":1786629708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04455-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4455"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04455-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04519-y","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04519-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests. M.W.: honoraria from Eli Lilly, Boehringer Ingelheim, SYNLAB, Janssen, Merck Serono, GWT, Amgen, Novartis, Pfizer, Bristol Myers Squibb, Regeneron, MJH Life Sciences\/Physicians\u02bc Education Resource, Takeda and AstraZeneca; consulting or advisory roles for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Immatics, Iovance Biotherapeutics, ISA Pharmaceuticals, Eli Lilly, Novartis, PharmaMar, Regeneron, Roche, T-knife Therapeutics, Tacalyx and Zymeworks; research funding (to institution) from Roche, Iovance Biotherapeutics and Boehringer Ingelheim; and travel support from Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, GEMoaB, Immatics, Iovance Biotherapeutics, Janssen Oncology, Merck Serono, Pfizer and Sanofi\/Aventis. S.O.: honoraria from MSD, Merck, Janssen, Immunocore, Pfizer and Ipsen and travel support from Ipsen, Pfizer, Merck and Janssen. H.B.: honoraria from Astellas, Bristol Myers Squibb, GlaxoSmithKline, Eli Lilly, MSD, Novartis, Pierre Fabre Pharma, Servier and Takeda and travel support from Jazz Pharmaceuticals and Novartis. A.B.: consulting fees (to self unless otherwise specified) from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Roche, MSD, Novartis, Bayer, Pfizer and Sanofi; consulting fees (to institution) from Onkowissen.de; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bristol Myers Squibb, AstraZeneca, Novartis, Eli Lilly, MSD, Janssen, Daiichi Sankyo, Roche, Sanofi, Takeda and Boehringer Ingelheim; travel support from Merck, Bristol Myers Squibb, Roche and Eli Lilly; participation on data safety monitoring boards or advisory boards for Bayer, Bristol Myers Squibb, Pfizer, Amgen, Boehringer Ingelheim, Merck, MSD, Novartis and Roche; and leadership roles in the AIO thoracic oncology steering group, the AIO translational oncology steering group and the AIG-FIO of the German Cancer Society, all outside the submitted work. F.B.: research grants from Roche and AstraZeneca; consulting fees from Immatics; honoraria from Novocure, Daiichi Sankyo, GlaxoSmithKline and AstraZeneca; travel support from Janssen, Roche and AstraZeneca; and participation in advisory boards for Bristol Myers Squibb, AstraZeneca, Daiichi Sankyo, Janssen, Regeneron and Pfizer. S.G.: relationships with Bristol Myers Squibb, Pfizer, Sobi, GlaxoSmithKline and AbbVie. M. Haenel reports honoraria from Kite\/Gilead, Bristol Myers Squibb and Johnson & Johnson\/Janssen and consulting or advisory roles for Amgen, BeiGene, Bristol Myers Squibb, Johnson & Johnson\/Janssen, Kite\/Gilead, Sanofi and Sobi. J.S.H.: consulting and\/or speaker fees and\/or travel support from Johnson & Johnson, Bristol Myers Squibb, Kite\/Gilead, AbbVie, Servier, Novartis, Roche, Iovance Biotherapeutics, Immatics, Philogen, Boehringer Ingelheim, Immunocore, Autolus and Kyverna. S.L.: advisory board participation and honoraria from Merck Sharp & Dohme, Bristol Myers Squibb, GlaxoSmithKline and Boehringer Ingelheim; travel support from Merck Healthcare and Boehringer Ingelheim; and a pending patent for a peptide vaccine warehouse (EP 22 187 930.7). M.S.: travel reimbursement from Merck and Pfizer; advisory roles for AstraZeneca, Regeneron and Gilead; lecture fees from BeOne Medicines; research funding from AstraZeneca, BeOne Medicines and Gilead; and data safety monitoring board membership for CureVac and Amgen. N.H., M. Hofmann, M. Hutt, A.M.-M., S.M., M.R., H.S., O.V., C.M.B. and C.R. are employees of Immatics and may hold stock and\/or stock options in the company. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}